# Medical Devices Market

> 医疗器械市场研究报告按设备类型（诊断设备、给药系统、侵入设备、呼吸治疗设备、电子医疗设备）、按应用（肿瘤学、心血管疾病、诊断成像、骨科、普通外科）、最终用户（医院和诊所、门诊手术中心、家庭护理机构）和区域（北美、欧洲、南美、亚太地区、中东和非洲）-行业预测到 2035 年。

- **Forecast Period:** 2026-2035
- **CAGR:** 7.5%
- **2025:** USD 720 Billion (2025)
- **2035:** USD 1,484 Billion (2035)
- **Key Players:** Medtronic, Johnson & Johnson MedTech, Abbott Laboratories, Siemens Healthineers, GE HealthCare, Philips, Boston Scientific, Stryker

**Report ID:** MRFR/MED/2123-CR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** October 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/medical-devices-market-2869

---

## Market Summary

Global Medical Devices Market Size was valued at USD 641,899 Million in 2024 & the market is projected to grow from USD 688,180 Million in 2025 to USD 1,377,540 Million by 2035, registering a CAGR of 7.21% during the forecast period 2025–2035. North America led the market with over 40% share, generating around USD 256759.60 million in revenue.
 
Rising prevalence of chronic diseases and the expanding elderly population are major growth drivers for the medical devices market, increasing demand for diagnostic imaging, wearable monitoring systems, minimally invasive surgical technologies, and AI-enabled healthcare solutions that improve treatment precision, patient outcomes, and operational efficiency globally.
 
According to WHO Data Portal, noncommunicable diseases account for approximately 41 million deaths annually, representing nearly 74% of total global deaths. Additionally, the growing aging population and increasing healthcare utilization are significantly accelerating adoption of advanced diagnostic, monitoring, and therapeutic medical devices across hospitals and specialty care centers worldwide.

## Market Drivers

### Growing Geriatric Population and Chronic Disease Burden

全球老年人口的增长是医疗器械市场的重要驱动力。随着人们年龄的增长，他们更容易患慢性和与年龄相关的健康问题，如心血管疾病、糖尿病、癌症、关节炎和中风。
 
这些情况需要持续监测、及时诊断和有效管理，所有这些都对先进医疗设备（包括诊断工具、监测系统、手术器械和康复设备）的需求不断增加。
 

- 根据 IHME 的数据，全球每年有近 4300 万人死于非传染性疾病，其中超过 1900 万人死于心血管相关疾病。不断增加的老年人口和慢性病患病率极大地推动了全球医疗机构对诊断成像系统、患者监测技术、手术设备和康复设备的需求。

### Technological Advancements and Integration of Ai in Devices

快速的技术进步正在提高医疗保健服务的精度、效率和有效性，从而改变医疗设备市场。成像、机器人、可穿戴传感器和微创手术工具方面的创新正在实现更准确的诊断并改善患者的治疗效果。这些发展降低了程序风险，缩短了恢复时间，并简化了工作流程，使医疗保健系统更加高效和可靠。
 
因此，医疗保健提供商越来越多地采用先进设备，从而推动整个市场的增长。总体而言，技术创新和人工智能集成的融合是医疗器械行业的重要增长动力。制造商正在投资研发，推出智能、互联和自动化设备，以满足不断变化的临床需求。这一趋势正在为支持精准医疗、个性化护理和数据驱动的医疗保健解决方案的下一代医疗设备创造机会，从而扩大全球市场。
 

- 据 PubMed 称，人工智能辅助诊断技术在多种放射学和疾病检测应用中已证明准确率超过 90%。人工智能成像、机器人辅助手术、可穿戴监测设备和互联医疗平台的日益普及，显着提高了整个医疗设备行业的诊断效率、临床精度、工作流程自动化和个性化患者护理。

### Rising Adoption of Ophthalmic Viscoelastic Devices in Cataract and Refractive Surgeries

[眼科粘弹性装置](https://www.marketresearchfuture.com/reports/ophthalmic-viscoelastic-devices-market-1396)(OVD) 在现代眼科手术中发挥着重要作用，特别是白内障和屈光手术。这些粘弹性解决方案有助于维持眼内空间，以保护脆弱的眼组织并促进手术期间的精确操作。由于人口老龄化和视力相关健康意识的提高，全球白内障和屈光手术持续增加，对 OVD 的需求大幅增长，这使其成为眼科手术的重要组成部分。
 
总体而言，白内障和屈光手术的日益流行，加上粘弹性解决方案在提高手术精度和安全性方面的关键作用，是眼科医疗器械市场的强劲增长动力。持续的产品创新，包括下一代生物相容性配方，预计将进一步加速采用并扩大这一利基但快速增长的细分市场的机会。
 

- 根据世界银行健康数据，全球预期寿命已超过 73 岁，导致易患白内障和视力障碍的老年人口迅速增长。全球白内障手术量的不断增加显着增加了对眼科粘弹性装置的需求，支持改善眼科和屈光手术中的眼内保护、手术精度和恢复结果。

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Regulatory fragmentation (EU MDR, IVDR complexity) | −0.6% | Europe | Medium-term (2–4 yr) | [2] |
| Reimbursement uncertainty for novel devices | −0.5% | North America, Europe | Short-term (≤2 yr) | [12] |
| Cybersecurity and data-privacy liabilities | −0.4% | Global | Long-term (≥4 yr) | [13] |
| Rare-earth and semiconductor supply-chain risk | −0.3% | Global | Medium-term (2–4 yr) | [14] |
| Skilled workforce shortages in biomedical engineering | −0.3% | Global | Long-term (≥4 yr) | [15] |

### EU MDR and Regulatory Fragmentation

Europe's transition from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) has forced manufacturers to re-certify thousands of legacy products, with compliance costs exceeding EUR 10 billion cumulatively across the continent [[2]](https://ec.europa.eu). Notified-body capacity remains a bottleneck — only 39 bodies were designated as of mid-2025, down from 58 under the MDD regime. The result is a certification queue that has pushed product launches back by 12–18 months and caused some smaller firms to exit the European Medical Devices Market entirely.

### Reimbursement Uncertainty for Novel Devices

In both the U.S. and Europe, payers are demanding more and more real-world evidence (RWE) before providing coverage codes for breakthrough devices, thus prolonging the commercial ramp-up from regulatory clearance to first reimbursable procedure by 6–12 months [[12]](https://advamed.org). Manufacturers investing in SaMD (Software as a Medical Device) are especially vulnerable, as payer classification systems have not kept up with regulatory taxonomies. This lag restrains the Medical Devices Market by delaying revenue recognition on some of the fastest growing product types.

### Cybersecurity and Data-Privacy Liabilities

More than 70% of new device registrations in the U.S. are currently from connected devices. However, the FDA’s pre-market cybersecurity guidelines, established in the PATCH Act of 2023, add testing expenses of USD 200,000-500,000 each submission [[13]](https://fda.gov). Disclosure requirements for vulnerabilities after market generate continuing responsibility. This is especially true for implantable devices when a firmware upgrade carries therapeutic risk. These rules put a structural cost burden on the Medical Devices Market that disproportionately affects small and mid-size inventors.

## Opportunities

## Medical Devices Market Opportunities

### Wearable Diagnostics for Chronic Disease Management

Continuous [biosensors](https://www.marketresearchfuture.com/reports/global-biosensors-market-833) for glucose, blood pressure and heart rhythm have moved from premium consumer wearables to prescription-grade diagnostics. The growth of CMS reimbursement, combined with the transition to value-based care, opens up a revenue route for manufacturers that can deliver outcomes data at scale. This category could, in fact, represent an added USD 45-60 billion of the Medical Devices Market by 2035 as usage goes beyond diabetes to heart failure and COPD populations.

### Surgical Robotics Penetration in Emerging Markets

Robotic-assisted surgery is making its way in China, India and Brazil, where governments are subsidizing capital acquisitions to solve surgical backlogs. In 2024, China’s National Healthcare Security Administration approved reimbursement for robotic prostatectomy, and India’s Ayushman Bharat scheme is conducting robotic orthopedic surgery at 15 tertiary hospitals [[9]](https://pmjay.gov.in)[[11]](https://intuitive.com). These programs are a multi-billion-dollar greenfield for the Medical Devices Market in price-sensitive, high-volume geographies.

### Data Monetization Through Device-as-a-Platform Models

Manufacturers are shifting from one-time capital sales to subscription and per-procedure pricing that bundles devices with analytics dashboards, remote monitoring, and predictive maintenance. Medtronic's GI Genius intelligent endoscopy platform and Abbott's LibreView cloud ecosystem exemplify this transition. The recurring-revenue model expands the addressable Medical Devices Market by layering software margins atop hardware economics.

### Infection-Resistant Smart Materials

Device-associated infections cost the U.S. healthcare system an estimated USD 9.8 billion annually [[10]](https://sciencedirect.com). Nanocoatings, antimicrobial surface treatments, and drug-eluting materials present a platform opportunity to command premium pricing on [orthopedic implants](https://www.marketresearchfuture.com/reports/orthopedic-implant-market-838), central-line catheters, and ventilator circuits. The Medical Devices Market will see accelerating adoption as hospital value-analysis committees incorporate infection-prevention metrics into procurement scoring.

### Point-of-Care Diagnostics in Low-Resource Settings

Sub-Saharan Africa and South Asia together represent over 3 billion people with limited access to centralized laboratory infrastructure. Portable, battery-powered diagnostic devices — such as handheld ultrasound and lateral-flow molecular assays — address this gap at price points under USD 5,000 per unit. International donor funding from the Global Fund and Gavi is providing the demand-side subsidy needed to scale these platforms within the broader Medical Devices Market.

## Future Outlook

## Medical Devices Market Future Outlook

### Algorithmic Diagnostics and Autonomous Decision Support

By 2030, AI-enabled diagnostic devices are expected to account for over 20% of new 510(k) clearances, transforming the Medical Devices Market from a hardware-centric to a software-layered ecosystem [[3]](https://fda.gov)[[7]](https://.com). Autonomous decision-support systems in radiology, pathology, and cardiology will shift competitive advantage toward companies that control proprietary training datasets and can demonstrate regulatory-grade algorithm validation at scale.

### Platform Economics and Subscription-Based Procurement

The transition from capital-equipment sales to platform-based, per-procedure pricing will reshape hospital-manufacturer relationships throughout the Medical Devices Market over the next decade. Companies that bundle device hardware, cloud analytics, and remote monitoring into unified subscription contracts will capture higher lifetime customer value, while hospitals will benefit from OPEX-friendly budget structures that align spending with utilization.

### Supply-Chain Regionalization and Rare-Earth Diversification

Geopolitical tensions and pandemic-era disruptions have triggered a structural shift toward regional manufacturing in the Medical Devices Market. The U.S. CHIPS and Science Act, the EU's Critical Raw Materials Act, and India's PLI scheme are all incentivizing domestic production of sensors, semiconductors, and specialty polymers used in device manufacturing [[14]](https://commerce.gov). By 2032, an estimated 40% of devices sold in North America will be manufactured within the continent, up from 28% in 2024.

### ESG Reporting and Sustainable Device Design

Sustainability reporting mandates — including the EU's Corporate Sustainability Reporting Directive (CSRD) and the SEC's climate-disclosure rules — are compelling device manufacturers to quantify and reduce the carbon footprint of their product portfolios [[19]](https://ec.europa.eu). Single-use device reprocessing, biodegradable packaging, and sterilization-energy optimization will become procurement criteria rather than voluntary initiatives, creating a new axis of differentiation in the Medical Devices Market by the late 2020s.

## Segment Insights

### 按应用分类：诊断设备（最大）与治疗设备（增长最快）

应用领域至关重要，揭示了各个类别之间的独特动态。诊断设备在医疗设备市场中占有最大份额，占 56%，是早期疾病检测和患者评估的重要工具。 它们之所以受到青睐，不仅是因为它们的功效，还因为它们越来越多地融入个性化医疗。相反，治疗设备正在迅速兴起，反映出以患者为中心的护理方法和先进治疗方式的增长趋势。

GE Healthcare 继续在全球医疗保健系统中扩展人工智能成像、超声和诊断监测技术。该公司的年收入约为 196 亿美元，业务遍及 160 多个国家，先进的诊断生态系统支持医院和专业医疗机构越来越多地采用早期疾病检测解决方案和精准诊断。

### 按最终用途：医院（最大）与家庭护理（增长最快）

在市场上，医院目前是最大的最终用途部分，由于对先进医疗技术的高需求以及在这些设施中执行的广泛手术，占据了 62% 的份额。 诊所也做出了巨大贡献，但随着越来越多的患者更喜欢门诊治疗，其份额正在稳步下降。家庭护理正在蓬勃发展，显示出向个性化医疗保健和远程监控的转变，而这一流行病强调减少医院就诊，进一步加速了这一转变。

家庭护理（主导）与研究实验室（新兴）

由于需要复杂多样的医疗设备来进行各种治疗和手术，医院仍然是市场的主导者。然而，在远程医疗和远程医疗创新的推动下，家庭护理正在成为一个强大的领域。 [远程病人监护](https://www.marketresearchfuture.com/reports/remote-patient-monitoring-market-10905)满足消费者对便利和独立的渴望。研究实验室专注于开发尖端技术和测试新设备，但其市场份额相对较小，因为它们主要依赖于资金和与较大医疗实体的合作。因此，虽然医院和家庭护理占据主导地位，但研究实验室通过推动医疗进步的界限发挥着至关重要的支持作用。

### 按设备类型：机电设备（最大）与植入设备（增长最快）

在各种设备类型中，机电设备在医疗设备市场中占有最大份额，占 48%，这反映了它们在诊断和治疗应用中不可或缺的作用。 手术器械和体外诊断设备紧随其后，为专门的医疗程序和实验室环境提供服务。可穿戴设备正在受到越来越多的关注，但与现有的机电和植入式设备相比，它们所占的市场份额仍然较小。

机电设备（主导）与可穿戴设备（新兴）

机电设备仍然是市场的基石，以其在各种临床环境中的可靠性和多功能性而闻名。它们涵盖从诊断机器到治疗设备的广泛产品。与此同时，在技术进步和消费者对健康监测兴趣日益浓厚的推动下，可穿戴设备正在成为重要的市场参与者。它们的特点是用户友好性和实时数据收集能力，这使得它们在预防性医疗保健中特别有吸引力。随着市场的发展，这两个细分市场可能会协同创新，重新定义患者护理。

### 按技术分类：数字技术（最大）与远程医疗（增长最快）

医疗器械市场日益受到各种技术进步的影响，数字技术在不同细分市场中占据最大份额，占 52%。数字技术包括软件驱动设备、远程监控和数据分析工具，在改善医疗保健环境中的患者治疗效果和运营效率方面发挥着至关重要的作用。远程医疗虽然目前规模较小，但随着医疗保健提供商采用虚拟咨询和远程患者管理解决方案，其影响力正在迅速扩大。

技术：数字技术（主导）与远程医疗（新兴）

数字技术的特点是与信息技术系统集成，可以对患者进行实时监控和管理。该细分市场使医疗保健提供商能够做出数据驱动的决策并增强整体患者体验。另一方面，远程医疗已成为市场上的一项重要服务，因为它能够接触偏远地区的患者并降低与传统医疗服务相关的成本。随着患者越来越青睐便捷的医疗服务，远程医疗领域有望实现显着增长，从而改变患者护理模式。

### 按监管分类：II 类设备（最大）与 III 类设备（增长最快）

该市场在各种监管分类中呈现出明显的分布，其中 II 类设备占据医疗设备市场的最大份额，占 50%。 这些设备包括输液泵和手术激光器等必需品，由于其中等风险分类，占据了整个市场的很大一部分。相比之下，需要更严格监管审查的 III 类设备代表了增长最快的细分市场，占 30% 的份额。这包括植入式起搏器和冠状动脉支架等高风险设备，反映出人们对先进医疗技术和患者护理的日益关注。

II 类设备（主导）与 III 类设备（新兴）

II 类设备因其广泛的应用和既定的监管途径而占据着市场份额。它们满足广泛的需求，平衡患者护理的安全性和可及性。虽然 III 类设备代表了一个具有巨大增长潜力的新兴行业，但它们的特点是更高的监管要求和创新。随着技术的进步允许更复杂的解决方案（例如生物工程植入物和先进的诊断设备），这一领域变得越来越重要，这表明向更复杂的医疗保健解决方案的转变。

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 48% revenue share (2025) | AI-device regulation, value-based procurement |
| Europe | 25% revenue share (2025) | MDR compliance, robotic surgery adoption |
| Asia-Pacific | 8.1% CAGR (2026–2035) | Insurance expansion, domestic manufacturing |
| South America | USD 36 Billion (2025) | Public hospital modernization |
| Middle East & Africa | USD 29 Billion (2025) | Greenfield hospital construction |
| Total | USD 720 Billion (2025) | — |

The Medical Devices Market exhibits pronounced geographic concentration in North America and Europe, though the growth center of gravity is shifting toward Asia-Pacific and select emerging economies.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 82% of regional share | CMS reimbursement breadth, FDA pathway speed |
| Canada | 9% of regional share | Provincial health authority procurement cycles |
| Mexico | CAGR 8.3% | Nearshoring of device assembly, IMSS modernization |

The United States alone accounts for over USD 283 billion of the North American Medical Devices Market, reflecting the world's deepest commercial payer ecosystem and the FDA's globally recognized regulatory pathway [[3]](https://fda.gov). Canada's single-payer system concentrates procurement through provincial health authorities, creating longer sales cycles but higher per-contract values. Mexico is emerging as a nearshoring hub for device sub-assembly, with export-oriented manufacturing growing 12% year-over-year as U.S. importers diversify away from Asian supply chains [[14]](https://commerce.gov).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 27% of regional share | Medtech manufacturing base, DRG reimbursement |
| United Kingdom | CAGR 7.2% | NHS digital transformation programs |
| France | USD 26 Billion (2025) | HAS device evaluation reforms |
| Italy | 12% of regional share | Cardiovascular device demand |
| Spain | CAGR 6.8% | Public-private hospital partnerships |
| Nordic Countries | USD 14 Billion (2025) | Digital health infrastructure leadership |
| Russia | 5% of regional share | Import substitution policies |
| Rest of Europe | CAGR 6.5% | Varying regulatory alignment with MDR |

Germany anchors the European Medical Devices Market with a dense cluster of medtech manufacturers and one of the continent's most device-friendly DRG reimbursement structures. The UK's NHS is channeling GBP 3.4 billion into digital and AI-driven diagnostic infrastructure through 2028, creating procurement demand across imaging, pathology, and remote monitoring platforms [[16]](https://england.nhs.uk). France's Haute Autorité de Santé is piloting accelerated device evaluations for breakthrough designations, which is expected to shorten market access timelines by 6–9 months.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 38% of regional share | Domestic medtech manufacturing, VBP reforms |
| Japan | USD 32 Billion (2025) | Surgical robotics, geriatric care demand |
| India | CAGR 9.4% | Ayushman Bharat expansion, Make in India |
| South Korea | 11% of regional share | Digital health regulation, K-medtech exports |
| ASEAN | CAGR 8.8% | Hospital construction boom, UHC programs |
| Rest of Asia-Pacific | USD 8 Billion (2025) | Early-stage market development |

Asia-Pacific represents the fastest-growing region in the Medical Devices Market, with India's 9.4% CAGR reflecting the compounding effect of insurance coverage expansion under Ayushman Bharat — which now covers over 500 million beneficiaries — and domestic manufacturing incentives under the Production-Linked Incentive scheme [[9]](https://pmjay.gov.in). China's volume-based procurement (VBP) program continues to compress ASPs on commodity devices like coronary stents and orthopedic implants, but total revenue growth persists as procedure volumes surge. Japan remains the region's premium market, with per-capita device spending exceeding USD 250.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 62% of regional share | SUS public hospital procurement |
| Argentina | CAGR 7.6% | Private-sector hospital investment |
| Rest of South America | USD 6 Billion (2025) | Pan-American Health Organization programs |

Brazil dominates the South American Medical Devices Market, with the Unified Health System (SUS) channeling federal procurement budgets toward [diagnostic imaging](https://www.marketresearchfuture.com/reports/diagnostic-imaging-market-6765) and surgical instrumentation upgrades at public tertiary hospitals. Argentina's private hospital sector is investing in imported imaging and cardiac devices as the peso stabilization cycle restores purchasing power [[17]](https://paho.org).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 31% of regional share | Vision 2030 healthcare infrastructure |
| UAE | CAGR 8.9% | Medical tourism, smart hospital construction |
| South Africa | USD 5 Billion (2025) | National Health Insurance reforms |
| Egypt | CAGR 7.8% | Population-driven demand, UHC pilot rollout |
| Rest of MEA | 22% of regional share | Donor-funded programs, basic infrastructure |

Saudi Arabia's Vision 2030 program is allocating over USD 65 billion to healthcare infrastructure, including 38 new hospitals and 22 specialized medical cities that will drive large-scale device procurement through the early 2030s [[18]](https://moh.gov.sa). The UAE's positioning as a regional medical-tourism hub is pushing smart-hospital construction projects that prioritize integrated digital operating theaters and AI-enabled imaging suites, creating premium-tier demand within the Medical Devices Market.

## Competitive Benchmarking

许多全球、区域和本地供应商是医疗器械市场的特征。市场竞争非常激烈，所有参与者都在争夺市场份额。激烈的竞争、技术的快速进步、政府政策的频繁变化以及环境法规是市场增长面临的关键因素。供应商根据成本、产品质量、可靠性和政府法规进行竞争。 
 
供应商必须提供具有成本效益的高质量产品，才能在竞争激烈的市场中生存并取得成功。该市场的主要参与者包括强生公司、通用电气医疗保健公司、史赛克公司、贝克顿迪金森公司、[波士顿科学公司](https://www.bostonscientific.com/en-US/healthcare-professionals/products.html)、雅培战略市场发展和决策以提高运营效率。
 

- 据世界卫生组织统计，全球有超过200万种不同类型的医疗器械，而FDA监管的医疗器械产品超过19万种，凸显了激烈的竞争和创新规模。此外，全球医疗保健支出超过 9 万亿美元 (IHME)，增强了市场的强劲投资和竞争活力。

## Recent News & Developments

## Recent News & Developments

- Abbott Laboratories (September 2024 ): Launched the FreeStyle Libre 3 Plus continuous glucose monitor with 15-day wear and integrated ketone sensing, targeting intensive insulin management populations [[20]](https://acc.org).
- U.S. FDA (October 2024): Published updated cybersecurity guidance for pre-market device submissions under the PATCH Act, requiring software bill-of-materials disclosure for all connected devices [[13]](https://fda.gov).
- Stryker (January 2022 ): Acquired Vocera Communications' remaining clinical workflow platform assets, integrating real-time communication into its surgical ecosystem [[22]](https://stryker.com).

## Report Scope

- September 2026, Medtronic received FDA clearance and a CE Mark for the latest Affera Prism-2 Mapping Software. It also received a CE Mark for the PulseSelect ProxBox Adapter with Proximity Indicator software. Prism-2 adds mapping tools such as Beat Matching and Pace Tagging, and it supports procedures that use little or no fluoroscopy. The adapter gives real-time tissue-proximity feedback before pulsed field ablation (PFA) energy is delivered. This shows Medtronic strengthening the software layer of its fast-growing cardiac ablation business. (Source: [news.medtronic.com](https://news.medtronic.com/2026-09-30-Medtronic-announces-regulatory-milestones-for-newest-cardiac-mapping-and-ablation-software))
- September 2026, Siemens Healthineers announced the global launch of its Innovance D-Dimer 2.0 assay, which has FDA 510(k) clearance and CE mark status. The test helps clinicians exclude deep vein thrombosis and pulmonary embolism in outpatients and is designed for rapid STAT lab testing. This is a diagnostics product, so it sits at the in-vitro-diagnostics end of "medical devices". It widens Siemens Healthineers' coagulation menu in a time-critical use case. (Source: [clpmag.com](https://clpmag.com/disease-states/cardiovascular/siemens-healthineers-fda-cleared-d-dimer-blood-test-launch/))
- September 2026, Abbott has begun rolling out SimpleScreen CRC, a blood-based colorectal cancer screening test for average-risk adults 45 and older, which it sells exclusively in the U.S. It is sold alongside the stool-based Cologuard Plus from Abbott's Exact Sciences acquisition. The FDA approval triggered a $100 million milestone payment from Abbott to Freenome. This moves Abbott's cancer-diagnostics portfolio into blood-based screening, where it competes with Guardant's Shield. The Sept 30 rollout date comes from a MassDevice headline and excerpt that I could not open in full, so the July approval links are the fully verified part. (Source: [medtechdive.com](https://www.medtechdive.com/news/freenome-secures-fda-nod-for-blood-based-colorectal-cancer-test/826290/))

## Frequently Asked Questions

**Q: 哪种采购模式为医院影像系统提供最佳的拥有总成本？**
A: 订阅和管理设备服务合同越来越超越前期资本购买，MRI和CT的成本转移到可预测的运营支出，同时捆绑维护、升级和人工智能软件许可证[7]。医院报告在这些模式下十年的总成本降低了15-20%。

**Q: 设备制造商如何在美国、欧盟和亚洲之间应对不同的监管路径？**
A: 大多数大型公司保持平行的监管团队，同时在FDA、欧盟通知机构和PMDA之间提交申请。模块化提交架构允许共享临床数据，并进行区域特定标签，从而将每个市场的提交成本降低约30%[12]。

**Q: 买方在连接设备采购中应要求哪些网络安全标准？**
A: 买方应要求符合IEC 62443标准、提供软件材料清单，并展示漏洞披露流程。2024年PATCH法案将这些作为美国的市场前要求[13]。

**Q: 基于价值的采购如何改变设备合同中的竞争动态？**
A: 医院将设备付款与记录的结果挂钩——再入院率、并发症发生率和住院时间减少。这奖励拥有强大真实世界证据（RWE）项目的制造商，并惩罚仅提供商品的供应商[12]。

**Q: 到2030年，哪些新兴设备类别可能会创造全新的报销代码？**
A: 用于物质使用障碍的数字治疗、闭环胰岛素输送系统和基于人工智能的病理平台是CMS在2030年前创造新CPT或HCPCS代码的主要候选者[1]。

**Q: 集团采购组织在塑造设备定价和市场准入中扮演什么角色？**
A: GPO通过医院网络整合采购力量，谈判低于标价15-25%的量折扣。制造商必须平衡GPO渠道的利润与直接到设施的关系，以保护高端产品线[22]。

**Q: 设备制造商如何将可持续性融入产品设计和包装中？**
A: 一次性设备再处理程序、可回收的灭菌包装和碳足迹标签正成为采购标准。欧盟CSRD要求披露范围3排放，推动制造商重新设计供应链[19]。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/medical-devices-market-2869*